Trulieve Cannabis Corp. quarterly report, Q2 FY2025

Trulieve Cannabis Corp. 10-Q Summary: Q2 2025

Business Context and Reporting Period

This filing covers the quarterly period ended June 30, 2025. Trulieve Cannabis Corp. is a vertically integrated, multi-state cannabis operator with retail and cultivation facilities in nine U.S. states. As of the reporting date, the company operated 231 dispensaries and 15 cultivation/processing facilities. The company is classified as a large accelerated filer.

Key Financial Metrics

Metric (in thousands) Q2 2025 Q2 2024 YTD 2025 YTD 2024
Revenue $302,086 $303,442 $599,846 $601,061
Gross Profit $182,926 $181,648 $366,145 $355,450
Gross Margin 60.6% 59.9% 61.0% 59.1%
Net Loss (GAAP) $(16,111) $(12,312) $(49,870) $(37,159)
Adjusted EBITDA $110,613 $106,957 $219,803 $212,752
Cash & Equivalents $392,580 $238,803 $392,580 $238,803
Operating Cash Flow (YTD) $136,831 $210,472 $136,831 $210,472
Total Debt (Long-Term) $612,914 $612,306 $612,914 $612,306

Note: Total Debt includes Private Placement Notes ($365.7M), Notes Payable ($108.5M), and Construction Finance Liabilities ($134.7M) as of June 30, 2025.

Material Changes vs. Prior Period

  • Revenue: Flat quarter-over-quarter (-0.4%) and year-over-year (-0.2%). Retail revenue declined due to price compression, partially offset by higher traffic and unit sales. Wholesale revenue increased due to expanded partnerships in Maryland, Ohio, and Pennsylvania.
  • Profitability: Gross margin improved to 60.6% (Q2) and 61.0% (YTD) driven by lower production costs. However, GAAP Net Loss widened to $16.1M (Q2) and $49.9M (YTD) primarily due to a significant increase in the provision for income taxes.
  • Expenses: Selling, General, and Administrative (SG&A) expenses decreased slightly in Q2 but increased YTD by $16.0M, largely driven by $13.1M in campaign and political contributions.
  • Liquidity: Cash and cash equivalents increased significantly to $392.6M from $238.8M at year-end 2024. Operating cash flow decreased YTD by $73.6M compared to 2024, attributed to the absence of a $59.3M tax refund received in Q1 2024 and higher political contributions.
  • Tax Liability: Uncertain tax position liabilities increased by $114.4M to $559.7M, reflecting accrued interest and penalties related to the company's position on IRC Section 280E.

Guidance, Outlook, and Risks

  • Outlook: Management believes existing cash balances are sufficient to meet requirements for the next 12 months. The company continues to invest in infrastructure, technology, and market expansion.
  • Regulatory Risk: Cannabis remains a Schedule-I controlled substance under federal law. The company faces risks of asset forfeiture and federal enforcement actions. The company is currently under examination by taxing authorities regarding IRC Section 280E.
  • Legislative Impact: The company is assessing the impact of the recently enacted "One Big Beautiful Bill Act" (H.R.1) on its financial statements.
  • Contingencies: A $6.5M liability was recorded related to a lease guarantee where a tenant defaulted. Additionally, $4.5M is reserved for pending litigation claims.
  • Forward-Looking Statements: The filing contains standard disclaimers regarding risks related to federal illegality, competition, and the ability to maintain licenses.

Investor Verification Checklist

  • Tax Position Viability: Verify the sustainability of the $559.7M uncertain tax liability and the company's legal stance on IRC Section 280E deductions.
  • Political Contributions: Review the $13.1M in campaign/political contributions included in SG&A and their impact on future operational leverage.
  • Debt Maturities: Confirm the ability to service $368M in private placement notes maturing in 2026.
  • Price Compression: Monitor retail pricing trends in key markets (Florida, Arizona, Pennsylvania) to assess if volume growth can offset margin pressure.
  • Legislative Changes: Track the implementation details of H.R.1 and potential changes to federal cannabis regulation.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.